Thursday Aug 28
BioTime to Collaborate With the University of Wisconsin and Louvain...
BioTime, Inc. today announced that it has entered into a collaboration with Susan Thibeault, Ph.D., of the University of Wisconsin and Marc Remacle, M.D. of Louvain University to evaluate BioTime's proprietary HyStem -based hydrogel for the treatment of vocal fold scarring.
Thursday Aug 28
Press release distribution, EDGAR filing, XBRL, regulatory filings
The Company is currently dra... BioTime to Collaborate With the University of Wisconsin and Louvain University in Test of HyStem-Based Hydrogel for Vocal Fold Scarring )--BioTime, Inc. today announced that it has entered into a collaboration with Susan Thibeault, Ph.D., of the University of Wisconsin and Marc Remacle,... )--Just in time for the ... (more)
BioTime Subsidiary Asterias Biotherapeutics Receives U.S. FDA...
BioTime, Inc. announced that its subsidiary Asterias Biotherapeutics, Inc. has received clearance from the U.S. Food and Drug Administration to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury.
Asterias Biotherapeutics Appoints Two Independent Directors and...
With these additions, the Asterias Board of Directors now comprises eight directors, three of whom are independent.
BioTime Announces Second Quarter 2014 Results and Recent Developments
BioTime, Inc. today reported financial results for the first quarter ended June 30, 2014 and highlighted recent corporate accomplishments.
BioTime (BTX) Announces Quarterly Results
BioTime issued its quarterly earnings data on Tuesday. The company reported EPS for the quarter, StockRatingsNetwork reports.